Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 14 - Serum markers for gynaecological cancer in the reproductive years

  • from SECTION 4 - Diagnostic Dilemmas
  • Edited by Sean Kehoe, Eric Jauniaux, Pierre Martin-Hirsch, Philip Savage
  • Book:
    Cancer and Reproductive Health
    Published online:
    05 October 2014
    Print publication:
    01 November 2008, pp 155-178

  • Summary

    This chapter focuses on the various tumour markers relevant to gynaecological malignancies in premenopausal women and their role in management. No serological markers have been found to be sufficiently sensitive for early-stage disease or specific for screening purposes. Squamous cell carcinoma antigen (SCC) is probably a marker of cellular differentiation of squamous cells. Beta human chorionic gonadotrophin (ßhCG) has been described as an 'ideal tumour marker' in gestational trophoblastic tumours (GTN) and plays a primary role in its management. Alpha-fetoprotein (AFP) has been used as a reliable marker for monitoring treatment and detecting early relapse in nonpregnant women. None of the serum markers has a well-established role in the clinical management of endometrial cancer. The role of serum CA125 in screening women in the reproductive age group with increased risk of familial ovarian cancer is being investigated.